Biologics Market, by Drug Class (Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides

Biologics Market, by Drug Class (Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides and Others (Peptide, Botulinum Toxin, and Others)), by Therapeutic Application (Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Biological products include wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for the treatment of genetic disorders. Biologics are also used to treat children with CLN2 disease, which is a form of Batten disease. Moreover, in 2017, BioMarin Pharmaceutical Inc. received the U.S. FDA approval for its Brineura (cerliponase alfa), which is indicated for the treatment CLN2 disease.

Market Dynamics

In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologics market. For instance, in 2017, Amgen Inc. received the U.S. Food and Drug Administration (FDA) for its Blincyto (Blinatumomab) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.

Furthermore, in 2017, Janssen Biotech, Inc. received the U.S FDA approval for Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma.

However, high cost of biologics for the treatment of diseases such as rheumatoid arthritis, cancer, multiple sclerosis, psoriasis, and other diseases is expected to hamper biologics market growth over the forecast period. For instance, according to the data published in NCBI in 2018, the cost of biologics for treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases can range from US$ 10,000 to US$ 30,000 per year in the U.S. and can exceed US$ 500,000 per year for the most expensive biologics.

Furthermore, it is more difficult to manufacture biologics than chemical drugs, as they are extremely sensitive due to its very complex molecules.

Key features of the study:

This report provides in-depth analysis of the global biologics market, market size (US$ Bn), and compound annual growth rate (CAGR (%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global biologics market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global biologics market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for Global Biologics Market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Biologics Market, by Drug Class:
Monoclonal Antibody
Vaccine
Recombinant Insulin
Human Growth Hormone
Blood Factor
Fusion Protein
Erythropoietin
Recombinant Enzyme
Interferon
Colony-stimulating Factor
Cell Therapy
Gene Therapy
Oligonucleotides
Others
Global Biologics Market, By Therapeutic Application:
Oncology
Metabolic Disorders
Autoimmune/Immunologic Diseases
Ophthalmic Diseases
Inflammatory Bowel Diseases (IBDs)
Respiratory Disorders
Neurological Disorders
Musculoskeletal Disorders (MSDs)
Cardiovascular Diseases (CVDs)
Infectious Diseases
Others
Global Biologics Market, by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Biologics Market, by Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Monoclonal Antibody
Vaccine
Recombinant Insulin
Human Growth Hormone
Blood Factor
Fusion Protein
Erythropoietin
Recombinant Enzyme
Interferon
Colony-stimulating Factor
Gene Therapy
Cell Therapy
Oligonucleotides
Others
By Therapeutic Application:
Oncology
Metabolic Disorders
Autoimmune/Immunologic Diseases
Ophthalmic Diseases
Inflammatory Bowel Diseases (IBDs)
Respiratory Disorders
Neurological Disorders
Musculoskeletal Disorders (MSDs)
Cardiovascular Diseases (CVDs)
Infectious Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Monoclonal Antibody
Vaccine
Recombinant Insulin
Human Growth Hormone
Blood Factor
Fusion Protein
Erythropoietin
Recombinant Enzyme
Interferon
Colony-stimulating Factor
Gene Therapy
Cell Therapy
Oligonucleotides
Others
By Therapeutic Application:
Oncology
Metabolic Disorders
Autoimmune/Immunologic Diseases
Ophthalmic Diseases
Inflammatory Bowel Diseases (IBDs)
Respiratory Disorders
Neurological Disorders
Musculoskeletal Disorders (MSDs)
Cardiovascular Diseases (CVDs)
Infectious Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Monoclonal Antibody
Vaccine
Recombinant Insulin
Human Growth Hormone
Blood Factor
Fusion Protein
Erythropoietin
Recombinant Enzyme
Interferon
Colony-stimulating Factor
Gene Therapy
Cell Therapy
Oligonucleotides
Others
By Therapeutic Application:
Oncology
Metabolic Disorders
Autoimmune/Immunologic Diseases
Ophthalmic Diseases
Inflammatory Bowel Diseases (IBDs)
Respiratory Disorders
Neurological Disorders
Musculoskeletal Disorders (MSDs)
Cardiovascular Diseases (CVDs)
Infectious Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Monoclonal Antibody
Vaccine
Recombinant Insulin
Human Growth Hormone
Blood Factor
Fusion Protein
Erythropoietin
Recombinant Enzyme
Interferon
Colony-stimulating Factor
Gene Therapy
Cell Therapy
Oligonucleotides
Others
By Therapeutic Application:
Oncology
Metabolic Disorders
Autoimmune/Immunologic Diseases
Ophthalmic Diseases
Inflammatory Bowel Diseases (IBDs)
Respiratory Disorders
Neurological Disorders
Musculoskeletal Disorders (MSDs)
Cardiovascular Diseases (CVDs)
Infectious Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Monoclonal Antibody
Vaccine
Recombinant Insulin
Human Growth Hormone
Blood Factor
Fusion Protein
Erythropoietin
Recombinant Enzyme
Interferon
Colony-stimulating Factor
Gene Therapy
Cell Therapy
Oligonucleotides
Others
By Therapeutic Application:
Oncology
Metabolic Disorders
Autoimmune/Immunologic Diseases
Ophthalmic Diseases
Inflammatory Bowel Diseases (IBDs)
Respiratory Disorders
Neurological Disorders
Musculoskeletal Disorders (MSDs)
Cardiovascular Diseases (CVDs)
Infectious Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Class:
Monoclonal Antibody
Vaccine
Recombinant Insulin
Human Growth Hormone
Blood Factor
Fusion Protein
Erythropoietin
Recombinant Enzyme
Interferon
Colony-stimulating Factor
Gene Therapy
Cell Therapy
Oligonucleotides
Others
By Therapeutic Application:
Oncology
Metabolic Disorders
Autoimmune/Immunologic Diseases
Ophthalmic Diseases
Inflammatory Bowel Diseases (IBDs)
Respiratory Disorders
Neurological Disorders
Musculoskeletal Disorders (MSDs)
Cardiovascular Diseases (CVDs)
Infectious Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Bristol-Myers Squibb Company (BMS) *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Merck & Co., Inc.
Roche AG
Merck KGaA
AstraZeneca Plc
Regeneron Pharmaceuticals, Inc
Novartis International AG
Pfizer, Inc.
Amgen, Inc.
AbbVie, Inc.
Sanofi S.A.
Eli Lilly & Company
Novo Nordisk A/S
Johnson & Johnson
GlaxoSmithKline Plc
Teva Pharmaceutical Industries Ltd.
Ipsen S.A.
Allergan Plc.

“*” marked represents similar segmentation in other categories in the respective section.